Renowned Medical Researcher & Colleague Publish Systematic Review of Serious Harms From COVID-19 Vaccines
Renowned Medical Researcher & Colleague Publish Systematic Review of Serious Harms From COVID-19 Vaccines
The review reveals major errors on the part of regulators, flawed health guidance recommendations, weak vaccine trials, underreporting of injury and a miscalculation of cost-benefit analysis.
Set Your Pulse: Take a breath. Release the tension in your body. Place attention on your physical heart. Breathe slowly into the area for 60 seconds, focusing on feeling a sense of ease. Click here to learn why we suggest this.
Dr. Peter Gøtzsche is a well known Danish physician with four decades of research experience, publishing 97 papers in the “big five” (BMJ, Lancet, JAMA, Annals of Internal Medicine, and New England Journal of Medicine) and 19 Cochrane reviews.
He is a co-founder of the Cochrane Collaboration, a British international charitable organization formed to organize medical research findings to facilitate evidence-based choices about health interventions involving health professionals, patients and policy makers.
Gøtzsche, along with medical scientist and investigative journalist Maryanne Demasi, PhD, have published a new paper titled “Serious harms of the COVID-19 Vaccines: A Systematic Review.”
It’s been a task for academics to look into this phenomenon given the fact that vaccine manufacturers and drug regulators never allowed independent researchers to examine the raw trial data, forcing transparency advocates to sue the FDA for access to the documents.
To conduct the review, the authors used a number of papers that have been published with data on serious adverse events (SAEs) associated with a COVID-19 vaccine.
The most important points outlined by the authors are as follows:
Many of the studies we reviewed were of very poor quality and published in journals that failed to identify fundamental errors.
The adenovirus vector vaccines increased the risk of venous thrombosis and thrombocytopenia. (Authorities have responded by suspending the use of AstraZeneca’s vaccine across many European countries, and in the US, regulators have advised restricted use of Janssen’s vaccine).
The mRNA-based vaccines increased the risk of myocarditis, with a mortality of about 1-2 per 200 cases. It was more common in younger males.
We found evidence of serious neurological harms, including Bell’s Palsy, Guillain-Barré syndrome, myasthenic disorder and stroke, which are likely due to an autoimmune reaction from mRNA and adenoviral vector vaccines.
Severe harms, i.e. those that prevent daily activities, were underreported in the randomized trials.
Severe harms were very common in studies of fully vaccinated people receiving boosters (3rd dose), and in a study of vaccination of previously infected people (i.e. those with naturally acquired immunity).
Drug regulators and other authorities have been very slow in following up signals of serious harms.
Given the difficulties of accessing regulatory data, obfuscations, and documented underreporting, we find it likely that there are other serious harms of the covid-19 vaccines, than those uncovered so far.
Population-wide recommendations for covid vaccination and boosters ignore the negative benefit to harm balance in low-risk groups such as children and people who have already recovered from covid-19 (natural immunity).
The authors also point out that, given all the difficulties and obstacles involved with getting access to regulatory data, obfuscations, and documented underreporting, it is likely that there are other serious harms than those uncovered so far.
You can refer to the study for more details regarding the methods used, and more. It’s just been published, is still in pre-print form, and has yet to go through peer-review.
Below are some of my most recent articles regarding all things COVID for those who are interested:
New Analysis Shows How The CDC Spread False Information That Exaggerated The Severity of COVID-19
Autopsy Results From People Who Died Unexpectedly Within Days of COVID-19 Vaccination
Medrxiv is down.
Let‘s hope it comes up again.
Found it there:
https://www.researchgate.net/publication/366099520_Serious_harms_of_the_COVID-19_vaccines_a_systematic_review/fulltext/6391dc31484e65005bf45ca2/Serious-harms-of-the-COVID-19-vaccines-a-systematic-review.pdf
Even using the limited information available to the public when the vaccines were introduced, it was evident that the manufacturers and regulators were being dishonest about safety. For instance, they claimed that the following incident that occurred during the trial was not related to the study product.
"A 25-year-old male with no past medical history and no concurrent medications experienced a transverse sinus thrombosis on Day 21 following vaccination. On Day 9 the participant experienced symptoms of fever, myalgia, headache, fatigue, abdominal pain, congestion and rhinorrhea. He tested negative for SARs-CoV-2 during this acute illness. Aside from headache, his symptoms improved. On Day 19 he experienced a tonic colonic seizure. A CT scan without contrast demonstrated a cerebral hemorrhage. On Day 21, a transverse sinus thrombosis was reported on a venogram. The participant underwent a thrombectomy as well as stent placement for stenosed right sigmoid sinus on Day 22. On Day 23 repeat venogram showed the presence of a new clot in the transverse sinus. A second thrombectomy with venoplasty was performed. Treating clinicians reported observing rapid thrombus formation during the two thrombectomy procedures that was consistent with a clinically hypercoagulable state. In their assessment, the transverse sinus thrombosis most likely occurred days before the participant's clinical presentation with a seizure; the seizure was reported to be a consequence of a secondary bleed caused by elevated venous pressure from the venous flow obstruction. Workup for hematologic and infectious causes of the thrombosis did not reveal an etiology. This event was initially thought to be related to the study product by the investigator and prompted a study pause. After thorough investigation and expert consultation no clear cause of the event was identified; however possible contributing factors, such as preceding infection and an anatomical anomaly, were suggested. The investigator’s brochure and informed consent form were updated accordingly, and the study pause was lifted. The investigator and Sponsor’s final assessment of this event was that it was not related to the study product."
SOURCE:
Vaccines and Related Biological Products Advisory Committee Meeting
February 26, 2021
FDA Briefing Document
Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19
https://www.fda.gov/media/146217/download